News

PipelineReview.com18m
Ascletis Announces First Participants with Obesity or Overweight Dosed in a U.S. 13-week Phase IIa Study of Small Molecule Oral GLP-1R Agonist ASC30
First participants with obesity or overweight with at least one weight-related comorbidity have been dosed in a U.S. 13-week Phase IIa study of small ...
PipelineReview.com41m
Theratechnologies enters into Definitive Agreement to be Acquired by CB Biotechnology, an Affiliate of Future Pak
MONTREAL, Canada I July 02, 2025 I Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage ...
PipelineReview.com20m
Neurizon Enters into Global License with Elanco to Accelerate Commercialisation of NUZ-001
Exclusive Global Rights: Neurizon is granted exclusive global rights to Elanco’s data package and related intellectual property for monepantel to develop and commercialise NUZ-001 and its related ...
PipelineReview.com42m
4DMT Announces Accelerated 4D-150 Phase 3 Development in Wet AMD and Streamlined Organization to Drive Late-Stage Execution
EMERYVILLE, CA, USA I July 02, 2025 I 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing ...